Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Tolerability of High Dose PURETHAL Mites in Allergic Rhinitis
NCT00973453Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Aug 2009
- Primary completion
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Purethal in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Aug 2009; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00973453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00973453.